Followers | 789 |
Posts | 123467 |
Boards Moderated | 19 |
Alias Born | 09/05/2002 |

Friday, March 31, 2023 11:35:39 AM
https://www.businesswire.com/news/home/20230330005697/en
FDA approval in this indication came in Jun 2022 (#msg-169240243).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Liked By
Spread the love. Be the first to like this post!
Recent BMY News
- Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer • Business Wire • 09/22/2023 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/20/2023 10:59:00 AM
- Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance • PR Newswire (US) • 09/17/2023 11:57:00 PM
- Friday’s Wall Street Highlights: Ford Motor, Arm, Salesforce, Adobe, Visa, MGM and more • IH Market News • 09/15/2023 01:32:41 PM
- Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day • Business Wire • 09/14/2023 12:30:00 PM
- Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer • Business Wire • 09/11/2023 10:59:00 AM
- Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study • Business Wire • 09/09/2023 10:01:00 PM
- Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research • Business Wire • 09/07/2023 11:00:00 AM
- Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference • Business Wire • 09/01/2023 10:59:00 AM
- U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions • Business Wire • 08/29/2023 02:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2023 09:28:48 PM
- Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) • Business Wire • 08/28/2023 03:26:00 PM
- Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform • PR Newswire (US) • 08/28/2023 12:00:00 PM
- Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023 • Business Wire • 08/25/2023 02:22:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/24/2023 06:17:32 PM
- Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments • Business Wire • 08/23/2023 11:55:00 AM
- BMY Gets European Approval for Opdivo as Treatment for Some Melanoma Patients • Dow Jones News • 08/22/2023 09:08:00 PM
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma • Business Wire • 08/22/2023 08:18:00 PM
- Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023 • Business Wire • 08/21/2023 10:59:00 AM
- Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer • Business Wire • 08/16/2023 02:19:00 PM
- Bristol Myers Sets $4 Billion Accelerated Stock Buyback • Dow Jones News • 08/10/2023 11:53:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:10:26 AM
- Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts • Business Wire • 08/10/2023 11:01:00 AM
- Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements • Business Wire • 08/10/2023 10:59:00 AM
- Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis • Business Wire • 08/08/2023 10:59:00 AM
Green Egg to launch $150 million bond offer for quicklime products production kiln plant Sep 22, 2023 12:11 PM
Nate's Food Co. Announces Reverse Merger and Change of Control with JP Energy Group to Drive Global Expansion • NHMD • Sep 22, 2023 9:00 AM
Trio Petroleum Corp Provides Update on Testing of the HV-1 Discovery Well • TPET • Sep 21, 2023 9:38 AM
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • GNPX • Sep 20, 2023 8:45 AM
Caduceus Provides Update on Its Plans for The Second Half of The Fiscal Year • CSOC • Sep 20, 2023 8:26 AM
RESILIENT ENERGY INC. (RENI) PURSUING ACQUISITION TARGETS • RENI • Sep 19, 2023 10:30 AM